Drug Profile
Research programme: 11-beta hydroxysteroid dehydrogenase inhibitors - Argenta
Alternative Names: CC1961Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Argenta Discovery
- Developer Argenta
- Class
- Mechanism of Action 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Memory disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Memory disorders in United Kingdom
- 31 Mar 2014 Argenta has been acquired by Charles River Laboratories
- 02 Feb 2010 Argenta Discovery has been acquired by Galapagos NV